IP receptor (prostacyclin pathway) drugs for Pulmonary Arterial Hypertension

8 tracked IP receptor (prostacyclin pathway) drugs in the Pulmonary Arterial Hypertension race. The class explanation lives on the IP receptor (prostacyclin pathway) page; the full indication pipeline across every mechanism is on the Pulmonary Arterial Hypertension page.

6 approved / phase 42 Phase 3

Head-to-head evidence: Epoprostenol vs Ralinepag · Epoprostenol vs Treprostinil (Orenitram) · Epoprostenol vs Treprostinil (Tyvaso) · Epoprostenol vs Treprostinil (Yutrepia, Liquidia) · Ralinepag vs Treprostinil (L606) · Ralinepag vs Treprostinil (Orenitram)

The roster

← all IP receptor (prostacyclin pathway) drugs